

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
September 19, 2017

**DRAFT MEETING ROSTER**

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Cindy Chee, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Harold J. Burstein, MD, PhD**

Institute Physician  
Dana-Farber Cancer Institute  
Associate Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

**Philip C. Hoffman, MD**

Professor of Medicine  
The University of Chicago  
Section of Hematology/Oncology  
Department of Medicine  
Chicago, Illinois

**Grzegorz S. Nowakowski, MD**

Associate Professor of Medicine and Oncology  
Mayo Clinic Rochester  
Rochester, Minnesota

**Courtney J. Preusse, MA**

*(Consumer Representative)*  
Senior Research Administrator and CLIA Operations  
Director  
Clinical Research Division  
Fred Hutchinson Cancer Research Center  
Seattle, Washington

**Alice T. Shaw, MD, PhD**

Director  
Center for Thoracic Cancers  
Massachusetts General Hospital  
Boston, Massachusetts

**Thomas S. Uldrick, MD, MS**

*(Acting Chairperson)*  
Clinical Director  
HIV & AIDS Malignancy Branch  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health (NIH)  
Bethesda, Maryland

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)**

**Phuong Khanh (P.K.) Morrow, MD, FACP**

*(Industry Representative)*  
Executive Medical Director, Amgen Oncology  
Therapeutic Area Head, US Medical Organization  
Thousand Oaks, California

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 19, 2017

**DRAFT MEETING ROSTER (cont.)**

---

**TEMPORARY MEMBERS (Voting)**

**Ronald M. Bukowski, MD**

Professor of Medicine  
Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University  
Bukowski Consulting, LLC  
Highland Heights, Ohio

**Susan Halabi, PhD**

Professor with Tenure  
Department of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, North Carolina

**Richard D. Lumley, MS, EdD**

*(Patient Representative)*  
Kansas City, Missouri

**Lance C. Pagliaro, MD**

Professor of Oncology  
Mayo Clinic College of Medicine and Science  
Senior Associate Consultant  
Division of Medical Oncology  
Department of Oncology  
Mayo Clinic  
Rochester, Minnesota

**Bruce Redman, DO**

Professor of Medicine  
Department of Internal Medicine  
Division of Hematology/Oncology  
University of Michigan Comprehensive Cancer  
Center  
Ann Arbor, Michigan

**Ramaprasad Srinivasan, MD, PhD**

Investigator and Head  
Molecular Cancer Therapeutics Section  
Urologic Oncology Branch  
Center for Cancer Research  
National Cancer Institute, NIH  
Bethesda, Maryland

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence &  
Acting Director  
Office of Hematology and Oncology Products  
(OHOP)  
Office of New Drugs (OND), CDER, FDA

**Julia Beaver, MD**

Acting Director  
Division of Oncology Products 1 (DOP1)  
OHOP, OND, CDER, FDA

**V. Ellen Maher, MD**

Clinical Team Leader  
DOP1, OHOP, OND, CDER, FDA

**Sundeep Agrawal, MD**

Clinical Reviewer  
DOP1, OHOP, OND, CDER, FDA

**Laura Fernandes, PhD**

Statistician  
Division of Biometrics V  
Office of Biostatistics  
Office of Translational Sciences, CDER, FDA

**James Xu, MD**

Clinical Reviewer  
DOP1, OHOP, OND, CDER, FDA